advertisement
11.14 Investigational drugs; pharmacological experiments (40)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Kopczynski CC
Drugs of Today 2018; 54: 467-478
78148 Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision
Sharif NA
Neural Regeneration Research 2018; 13: 1145-1150
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Mahalingam K
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78256 Old and New Drug Classes Expanding To Include Glaucoma Treatments
Kish T
P and T 2018; 43: 489-502
78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Jacob TF
Purinergic signalling 2018; 14: 271-284
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Tanna AP
Ophthalmology 2018; 125: 1741-1756
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Iwamura R
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fuwa M; Toris CB
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Tanaka M
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Chaurasia AK
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78293 Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension
Heah T
Drugs of Today 2018; 54: 467-478
78116 Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
Johnson M
Ophthalmology 2018; 125: 1741-1756
78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Singh V; Dixit M
Purinergic signalling 2018; 14: 271-284
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Okanari E
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gowtham L
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Fan S
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Kirihara T
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Ginsburg-Shmuel T
Purinergic signalling 2018; 14: 271-284
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Taniguchi T
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Gupta S
Indian Journal of Ophthalmology 2018; 66: 1104-1108
78100 Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl
Odani-Kawabata N
Journal of Medicinal Chemistry 2018; 61: 6869-6891
78127 A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
Fonseca B
Purinergic signalling 2018; 14: 271-284
78091 Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys
Ichikawa M
Journal of Ocular Pharmacology and Therapeutics 2018; 34: 531-537
78168 Therapeutic potential of valproic acid in advanced glaucoma: A pilot study
Somarajan BI
Indian Journal of Ophthalmology 2018; 66: 1104-1108
